ArticleResearch and practice in thrombosis and haemostasis2025
Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with hemophilia are reported to have a high prevalence of established and potential risk factors for kidney dysfunction and damage. However, comprehensive studies specifically evaluating kidney function in hemophilia, particularly hemophilia B (HB), are limited, with most research focusing on hemophilia A. Objectives: This study aimed to assess markers of glomerular filtration, damage, and tubular function in patients with HB enrolled in the B-Natural study. Methods: Kidney function and damage was evaluated using estimated glomerular filtration rate (eGFR), urine albumin/creatinine ratio, urinary immunoglobulin/creatinine ratio, and protein HC. Correlations with patient characteristics, treatment regimes, and comorbidities were analyzed. Results: The cohort consisted of 209 patients with HB, with 32% having severe, 51% moderate, and 17% mild disease. The median age was 13 years (IQR, 9-22 years; range, 1-73 years). The mean eGFR across the cohort was 107 mL/min/1.73 m Conclusion: Our findings suggest that patients with HB and no inhibitors do not have an increased risk of kidney dysfunction or damage compared to persons without hemophilia. Age and hypertension were the primary risk factors, underscoring the importance of regular follow-ups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.